Get the Stockscreener App
19.00
3.26%
0.60
Puretech Health Plc Adr stock is traded at $19.00, with a volume of 1,806.
It is up +3.26% in the last 24 hours and up +2.43% over the past month.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
See More
Previous Close:
$18.40
Open:
$18.95
24h Volume:
1,806
Relative Volume:
0.47
Market Cap:
$458.50M
Revenue:
$1.70M
Net Income/Loss:
$-47.01M
P/E Ratio:
-11.18
EPS:
-1.7
Net Cash Flow:
$-157.28M
1W Performance:
+5.50%
1M Performance:
+2.43%
6M Performance:
+2.87%
1Y Performance:
-13.64%
1-Day Range:
$18.62
$19.00
1-Week Range:
$18.20
$19.84
52-Week Range:
$13.30
$25.00
Puretech Health Plc Adr Stock (PRTC) Company Profile
Name
Puretech Health Plc Adr
Sector
Industry
Phone
-
Address
-
Compare PRTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
19.00 | 478.77M | 1.70M | -47.01M | -157.28M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
Puretech Health Plc Adr Stock (PRTC) Latest News
PureTech Health to report half-yearly results on August 28 By Investing.com - Investing.com South Africa
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health (NASDAQ:PRTC) Trading Up 1.4% – Still a Buy? - Defense World
PureTech Health (NASDAQ:PRTC) Shares Down 7.3% – Here’s What Happened - Defense World
PureTech’s Seaport doses first patient in phase 2b depression study By Investing.com - Investing.com South Africa
PureTech Health names Robert Lyne as interim CEO as Chowrira departs - Investing.com
PureTech Health names Robert Lyne as interim CEO as Chowrira departs By Investing.com - Investing.com India
Big Oil's Q2 Outlook: Downstream Gains and Upstream Pains - The Globe and Mail
PureTech Health announces board leadership transition By Investing.com - Investing.com South Africa
PureTech Health announces board leadership transition - Investing.com
PureTech Health announces board chair Raju Kucherlapati steps down - Investing.com
PureTech Health issues shares to executives following RSU vesting - Investing.com
PureTech Health announces RSU vesting and share transactions by PDMR - Investing.com
PureTech set for Jefferies Global Healthcare Conference chat By Investing.com - Investing.com India
PureTech set for Jefferies Global Healthcare Conference chat - Investing.com
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial - Placera.se
PureTech research reveals gaps in IPF patient care - Investing.com
PureTech research reveals gaps in IPF patient care By Investing.com - Investing.com South Africa
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ... By GuruFocus - Investing.com Canada
PureTech Health to release annual financial results April 30 - Investing.com
PureTech Health to release annual financial results April 30 By Investing.com - Investing.com South Africa
PureTech Health enlists Peel Hunt as joint broker - Investing.com
PureTech Health enlists Peel Hunt as joint broker By Investing.com - Investing.com India
Invesco Ltd: Form 8.3PureTech Health PLC; Opening Position disclosure - The Manila Times
PureTech Health in potential acquisition talks with Nordic Capital By Investing.com - Investing.com South Africa
PureTech Health in potential acquisition talks with Nordic Capital - Investing.com India
Nordic Capital XI ends pursuit of PureTech acquisition - Investing.com
PureTech Health issues shares to executives after RSU vesting - Investing.com India
PureTech Health issues shares to executives after RSU vesting By Investing.com - Investing.com South Africa
PureTech set for fireside chat at global healthcare event - Investing.com India
PureTech set for fireside chat at global healthcare event By Investing.com - Investing.com South Africa
FDA fast tracks PureTech's leukemia treatment - Investing.com
PureTech to present at J.P. Morgan Healthcare Conference By Investing.com - Investing.com India
PureTech reports positive LYT-200 trial results in AML/MDS - Investing.com
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
South Korea Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Top Biotech Stocks: Exploring Innovation Opportunities - MarketBeat
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
The definitive Boston biotech layoff tracker for 2023 - The Business Journals
This Emerging Market Could Be The Next Big Thing In Biotech - Barchart.com
Royalty Pharma and PureTech Health Enter KarXT Royalty Agreement for Up to $500M - Investing.com India
The Petri Dish: 1910 Genetics hires CBO; PureTech calls off merger - The Business Journals
Has Nextgen Healthcare (NXGN) Outpaced Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Predict an 82% Upside in PureTech Health PLC Sponsored ADR (PRTC): Here's What You Should Know - Nasdaq
PureTech Announces Annual Results for Year Ended December 31, 2020 - Samoa Observer
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
Puretech Health Plc Adr Stock (PRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):